Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Pharmathen S A is navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a balanced distribution of the current workload. KWON, YONG SOK serves as the busiest examiner, though they are responsible for only 1 busiest examiner pending action.
The presence of 2 distinct art units suggests that the portfolio covers diverse technical aspects within the broader biotechnology field. Practitioners should note that with 2 distinct examiners involved, the prosecution strategy must be tailored to two different sets of individual preferences. This diversity provides a buffer against the specific tendencies of any single examiner, as the 2 pending office actions are not concentrated under one person.
Because the busiest examiner pending count is 1, the workload is perfectly split between the identified examiners. This parity means that no single examiner currently dominates the company's immediate legal hurdles. Success in this portfolio requires maintaining consistent arguments across the 2 distinct art units while addressing the specific requirements of KWON, YONG SOK and the other unnamed examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17626625 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE | REYNOLDS, FRED H | 30d overdue |
| 17923330 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION COMPRISING BRIMONIDINE | KWON, YONG SOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17626625 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE | REYNOLDS, FRED H | 30d overdue |
| 17923330 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION COMPRISING BRIMONIDINE | KWON, YONG SOK | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17923330 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION COMPRISING BRIMONIDINE | KWON, YONG SOK | 1613 | §102§103§112Other | Non-Final OA | — | Pending | Nov 04, 2022 |
| 17626625 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE | REYNOLDS, FRED H | 1658 | §103§112Other | Final Rejection | 30d overdue | Pending | Jan 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial